The multicenter randomized study of the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico has provided the opportunity to analyze the impact of thrombolytic treatment on secondary ventricular fibrillation incidence in a large population of patients (11,712) with acute myocardial infarction. A reduction of about 20%So in the frequency of secondary ventricular fibrillatio...

A failure of hemostasis of the organism could cause the formation of clots inside the circulatory system, causing disorders of the system that lead to such processes like the stroke or myocardial infarction. The treatment of these pathologies could require the application of thrombolytic agents like the urokinase (Uk), the tissue type plasminogen activator (tPA) or the streptokinase (Sk). This ...

Thrombolytic therapy, also known as clot busting drug, is a breakthrough treatment which has saved untold lives. It has been used in the clinical area to treat venous and arterial thromboembolic complaints which are a foremost cause of death. In 1761, Morgagni lead the way of thrombolytic therapy. Now day's different types of thrombolytic drugs are currently available in market: alteplase, anis...

In recent years different regimens for reperfusion therapy in evolving myocardial infarction have been developed: intravenous streptokinase, accelerated tPA and direct angioplasty. The life saving effect of thrombolytic therapy has been established in a number of randomized trials, most of which tested streptokinase 1.5 million units administered over l h. The results have been summarized in th...

In this review paper, an emphasis is made to focus on the history, source, structure, mode of action, and application Nattokinase. The reveals that Nattokinase can act as a potent thrombolytic agent compared other agents which are commercially available. Studies NK have also be proved it useful for dissolving blood clots by converting plasminogen plasmin, further fibrin clots. been isolated fro...

Thrombolysis has become an accepted form of therapy for acute myocardial infarction. As demonstrated in the Global Utilization of Streptokinase and t-PA for Occluded Arteries trial, early, complete and sustained patency of the infarct-related coronary artery is correlated with reduced mortality. However, current thrombolytic regimens are able to achieve such patency within 90 min in only 81% of...

background: the use of thrombolytic agents in the treatment of hemodynamically stable patients with acute submassive pulmonary embolism (pte) remains controversial. we, therefore, conducted this study to compare the effect of thrombolytic plus anticoagulation versus anticoagulation alone on early death and adverse outcome following submassive pte. methods: w e conducted a study of patients with...

Lung Immunobiochemical Research Laboratory, Department of Cardiology, General Hospital, Birmingham; and Department of Cardiology, Queen Elizabeth Medical Centre, Birmingham M Lynch W A Littler B L Pentecost R A Stockley Correspondence to Dr Mary Lynch, Department of Cardiology, The General Hospital, Steelhouse Lane, Birmingham B4 6NH. Accepted for publication 29 April 1991 Abstract Objective-To...

Recent guidelines recommend bolus-dose alteplase for treating massive pulmonary embolism (PE). However, the safest and most effective treatment is as yet unknown. In the present study, a meta-analysis of published studies of alteplase infusion, bolus-dose alteplase and streptokinase was performed. The outcome measures were as follows: objective assessment of thrombolysis; all-cause mortality; d...